Ojal Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
- Paid Up Capital ₹ 5.86 M
- Company Age 6 Year, 29 Days
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 57.17%
- Profit Growth 163.46%
- Ebitda 166.12%
- Net Worth 123.29%
- Total Assets 44.66%
About Ojal Pharmaceuticals
Ojal Pharmaceuticals Private Limited (OPPL) is a Private Limited Indian Non-Government Company incorporated in India on 18 January 2019 (Six years 29 days old ). Its registered office is in Indore, Madhya Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 5.86 M, as per Ministry of Corporate Affairs (MCA) records.
Giriraj Gupta, Anil Chopra, Kirti Shah, and One other member serve as directors at the Company.
Company Details
-
Location
Indore, Madhya Pradesh, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24290MP2019PTC047557
-
Company No.
047557
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
18 Jan 2019
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Gwalior
Industry
What products or services does Ojal Pharmaceuticals Private Limited offer?
Ojal Pharmaceuticals Private Limited offers a wide range of products and services, including Anti Infective Drugs & Medicines, Antiviral Drugs.
Who are the key members and board of directors at Ojal Pharmaceuticals?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Giriraj Gupta
|
Director | 18-Jan-2019 | Current |
|
Anil Chopra
|
Director | 27-Dec-2019 | Current |
| Kirti Shah | Additional Director | 26-Jul-2024 | Current |
| Surbhi Gupta | Additional Director | 26-Jul-2024 | Current |
Financial Performance of Ojal Pharmaceuticals.
Ojal Pharmaceuticals Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 57.17% increase. The company also saw a substantial improvement in profitability, with a 163.46% increase in profit. The company's net worth Soared by an impressive increase of 123.29%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ojal Pharmaceuticals?
In 2021, Ojal Pharmaceuticals had a public holding of 11.21%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ojal Pharmaceuticals?
Unlock and access historical data on people associated with Ojal Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ojal Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ojal Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
